TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35809742
Drug: Ropivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine infusion via TAP catheter
Study: 32825845
Drug: Low-intensity intervention
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity intervention (standard treatment, guideline-based municipal smoking cessation program)
Study: 33884980
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2 μg/kg
Study: 34498946
Drug: rHuEPO (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (400 IU/kg body wt) injection
Study: 35281985
Drug: Intraparenchymal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraparenchymal injection of placenta MSC-derived Exosome
Study: 34894771
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral diazepam 5 mg and i.m. injection of pethidine)
Study: 34894771
Drug: Combined (acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (acupuncture + control drugs)
Study: 39615889
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution)
Study: 33293212
Drug: Icenticaftor 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icenticaftor 450 mg bid for 14 days
Study: 38810093
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg)
Study: 33624584
Drug: New favipiravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: New favipiravir tablet formulation
Study: 33624584
Drug: Reference favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Reference favipiravir tablet formulation
Study: 34548165
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg PO acetaminophen (group B)
Study: 616840380
Drug: Intraorbital electroacupuncture
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraorbital electroacupuncture therapy
Study: 616840380
Drug: Neural nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural nutrition drug (given to both groups)
Study: 35122085
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use >60 days/year
Study: 35493824
Drug: t-DCS (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: t-DCS (n = 13) for 5 daily sessions (20 min−2 mA) with bi-hemispheric stimulation over the primary motor cortex (M1)
Study: 32345452
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with suboccipital muscle inhibition and interferential current (20 minutes, twice weekly for 4 weeks)
Study: 33633687
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in daily GH dose (IGF-1 target level of 1 to 2 SDS)
Study: 33633687
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in daily GH dose (IGF-1 target level of -2 to -1 SDS)
Study: 35535532
Drug: Eperisone hydrochloride
Normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone hydrochloride tablets combined with TSLO brace, oral eperisone hydrochloride tablets 50 mg three times a day, wearing TSLO brace for not less than 8 hours a day for 4 weeks.
Study: 36209441
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms
Study: 35114667
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine (group A1)
Study: 33270038
Drug: Pro-vaccine posts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-vaccine posts (n=324)
Study: 33270038
Drug: Anti-vaccine posts
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-vaccine posts (n=256)
Study: 33270038
Drug: Most liked
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Most liked pro-vaccine post
Study: 33223228
Drug: 5% Lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Lidocaine Patch (LP)
Study: 35307066
Drug: NCPAP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCPAP combined with inhalation of pulmonary surfactant using vibrating mesh nebulizers
Study: 35307066
Drug: NCPAP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCPAP combined with inhalation of pulmonary surfactant using endotracheal tube (INSURE)
Study: 34344839
Drug: Octenidine solution
Normalized name: octenidine
DrugBank: Octenidine (DB12624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octenidine solution
Study: 35050943
Drug: Weierkang pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weierkang pills
Study: 34419090
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of colostrum
Study: 32467546
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (Metformin/Glibenclamide 500mg/5mg)
Study: 32467546
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (Metformin/Glibenclamide 500mg/5mg)
Study: 33511201
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (3 g of TXA in 100 mL saline after TKA)
Study: 33511201
Drug: Topical Floseal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Floseal® (10 mL of Floseal® intra-articularly during surgery)
Study: 33511201
Drug: Placebo (intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intra-articular saline injection only)
Study: 32420786
Drug: Curcumin (500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500-mg capsules twice daily)
Study: 33880813
Drug: Purslane extract
Normalized name: purslane extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purslane extract (300 mg/day)
Study: 32562683
Drug: Dulaglutide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (1.5 mg, subcutaneous injections once a week)
Study: 33333295
Drug: All tralokinumab
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All tralokinumab doses
Study: 35578315
Drug: Self-management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management of sedative therapy with dexmedetomidine
Study: 33884617
Drug: Dialectical behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behaviour therapy (DBT)
Study: 33573926
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg methylprednisolone
Study: 36949478
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT)
Study: 35118740
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture (AA) treatment for 8 weeks
Study: 34390762
Drug: Omarigliptin (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omarigliptin (once-weekly DPP-4 inhibitor)
Study: 34390762
Drug: Once-daily DPP-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily DPP-4 inhibitors (control)
Study: 34031050
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) treatment
Study: 36443540
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments
Study: 33396403
Drug: Food frequency
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food frequency questionnaire used to calculate food variety and food group diversity scores; low fruit and vegetable consumption: 24–47 months; 63.8 g (girls), 69.5 g (boys); 48–60 months; 68.3 g (girls), 74.4 g (boys); p = 0.037 (24–47 months), p = 0.038 (48–60 months)
Study: 32676727
Drug: Magnetic sphincter
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic sphincter augmentation (MSA)
Study: 39217573
Drug: Aspirin monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin monotherapy
Study: 35914511
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Clopidogrel
Study: 34495376
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg every day)
Study: 38353301
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg)
Study: 36157208
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus laparoscopic radical hysterectomy
Study: 36157208
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus open radical hysterectomy (control group)
Study: 34998900
Drug: Palliative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative chemotherapy (CT)
Study: 34636899
Drug: Burosumab therapy
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Burosumab therapy
Study: 33872197
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus fish skin graft applied weekly for up to 12 weeks
Study: 32728703
Drug: Integrase strand
Normalized name: Integrase strand transfer inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase strand transfer inhibitor (InSTI) resistance testing
Study: 32728703
Drug: Reverse transcriptase
Normalized name: Reverse transcriptase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverse transcriptase inhibitor and PI resistance testing
Study: 35947524
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (HDDT): amoxicillin 750 mg q.i.d. and esomeprazole 40 mg t.i.d.
Study: 35947524
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clarithromycin-containing bismuth quadruple therapy (ACBQT): esomeprazole 20 mg, bismuth potassium citrate 2 g, amoxicillin 1 g, and clarithromycin 500 mg; b.i.d.
Study: 33960071
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation (PMR) exercises, twice weekly for 8 weeks
Study: 37621153
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/day
Study: 33004727
Drug: Group Motivational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Motivational Therapy (GMT)
Study: 33004727
Drug: Individualised Motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised Motivational Therapy (IMT)
Study: 33851429
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists
Study: 34540188
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 ?g/kg loading dose for 15 min, followed by 0.4 ?g/kg/h until 30 min before surgery)
Study: 34540188
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline administered in the same manner)
Study: 34878707
Drug: Neostigmine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 50 µg/kg
Study: 34680123
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) adjunctive therapy (16 mg/mL cross-linked and 2 mg/mL non-cross-linked)
Study: 34680123
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-surgical periodontal therapy without HA)
Study: 32483134
Drug: Atorvastatin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (single 80-mg oral dose)
Study: 32304405
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (50 mg/kg loading dose for 15 min, followed by 15 mg · kg · h infusion)
Study: 39135452
Drug: Tofacitinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib treatment
Study: 35384093
Drug: Liberal oral
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal oral intake immediately after discharge from PACU
Study: 35384093
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral intake 6 hours after discharge from PACU
Study: 35384093
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral intake
Study: 35384093
Drug: Liberal oral
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal oral intake
Study: 32555601
Drug: True-immunized subjects
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: True-immunized subjects administered three booster immunizations
Study: 32116251
Drug: Genetically DBP
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically DBP levels (per 1 standard deviation (SD) increase 50 mg/L)
Study: 33717194
Drug: Zika purified-inactivated
Normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zika purified-inactivated virus (ZPIV) vaccine, 3 doses
Study: 33717194
Drug: Zika purified-inactivated
Normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zika purified-inactivated virus (ZPIV) vaccine in JEV pre-immunized individuals
Study: 33717194
Drug: Zika purified-inactivated
Normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zika purified-inactivated virus (ZPIV) vaccine in YFV pre-immunized individuals
Study: 33717194
Drug: Zika purified-inactivated
Normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zika purified-inactivated virus (ZPIV) vaccine in flavivirus-naïve individuals
Study: 35490585
Drug: Ultrasound-guided stellate
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided stellate ganglion injection
Study: 34794202
Drug: CitruSlim high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CitruSlim high-dose (HD, 400 mg)
Study: 34794202
Drug: CitruSlim low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CitruSlim low-dose (LD, 200 mg)
Study: 39532861
Drug: Ad26.COV2.S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S vaccine
Study: 32443348
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block with periarticular infiltration (30 mL of 0.5% ropivacaine and 100 mcg of clonidine)
Study: 631335334
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (control group)
Study: 34685778
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (control)
Study: 33896333
Drug: M7583 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M7583 at 80 mg (three days)/160 mg (full 28-day cycle), then 300 mg/day, 600 mg/day, 900 mg/day, and 300 mg twice daily
Study: 34716710
Drug: Dialogic book‐sharing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialogic book‐sharing (8 weekly group sessions)
Study: 33878282
Drug: Deprescribing anticholinergic
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprescribing anticholinergic medications (ACM) over 1 to 6 months with education directed at psychiatrists and clinical pharmacy support.
Study: 32527232
Drug: Glibenclamide (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (loading dose of 1.25 mg, followed by 0.625 mg every 8 hours for 5 days)
Study: 35831850
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (80 mg daily)
Study: 35151410
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 24 weeks)
Study: 35291004
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (30 mg/kg) and ethambutol (R30HZE)
Study: 37148831
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) therapy
Study: 34438469
Drug: High-dose colchicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose colchicine
Study: 34534800
Drug: 7-day internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day internet-based cognitive behavioral therapy (CBT)
Study: 34432514
Drug: Hydromorphone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.1 mg/kg, IM) alone (group H)
Study: 34432514
Drug: Hydromorphone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.1 mg/kg, IM) with acepromazine (0.05 mg/kg, IM; group AH)
Study: 34432514
Drug: Hydromorphone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.1 mg/kg, IM) with dexmedetomidine (6 µg/kg, IM; group DH)
Study: 37808864
Drug: Losartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan treatment
Study: 38281309
Drug: Macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan 10 mg
Study: 33792958
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg/d)
Study: 33268419
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous zinc (0.5 mg/kg)
Study: 36336851
Drug: Corticosteroid irrigation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid irrigation, Saline irrigation, No treatment
Study: 37140175
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT)
Study: 32713395
Drug: Nocturnal whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal whey protein ingestion (63 g whey protein)
Study: 35279338
Drug: Custom group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom group (alternative drugs based on pharmacogenetic testing)
Study: 34452970
Drug: CORKA (Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORKA (Community Rehabilitation after Knee Arthroplasty) home‐based rehabilitation, receiving a median five treatment sessions (IQR 4‐7)
Study: 36327275
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous butylscopolamine bromide
Study: 36327275
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (1 mL sodium chlorine 9 mg/mL)
Study: 32125929
Drug: ATRIPLA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRIPLA + rosemary methanolic extract (400 mg/day)
Study: 32208397
Drug: Prasugrel 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 3.75 mg (PRA3.75)
Study: 32208397
Drug: Prasugrel 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 2.5 mg (PRA2.5)
Study: 32208397
Drug: Clopidogrel 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 50 mg (CLO50)
Study: 34872404
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg for 7 days
Study: 35905752
Drug: Dolutegravir-based regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir-based regimen (50 mg dolutegravir, 300 mg tenofovir disoproxil fumarate, and either 200 mg emtricitabine in South Africa or 300 mg lamivudine in Uganda)
Study: 35905752
Drug: Efavirenz-based regimen
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz-based regimen (fixed dose combination 600 mg tenofovir disoproxil fumarate plus either emtricitabine in South Africa or lamivudine in Uganda)
Study: 36116413
Drug: MP2/cc‐pVTZ method
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP2/cc‐pVTZ method to calculate the Raman spectra of serine conformers
Study: 32926799
Drug: Curcuma longa
Normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma longa extract (CL) 2 capsules per day for 12 weeks
Study: 32926799
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo 2 capsules per day for 12 weeks
Study: 34298589
Drug: Dipyridamole plus
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole plus aspirin
Study: 35614473
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg codeine
Study: 35614473
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg codeine
Study: 34875345
Drug: Bifidobacterium breve
Normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium breve CCFM1025 (10^10 CFU daily for 4 weeks)
Study: 33658293
Drug: Placebo vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaccine
Study: 33142510
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vitamin E and omega-3 fatty acids during the starter phase (0-10 d)
Study: 33046214
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (represented by variants in the HMGCR gene region)